ATE184883T1 - Muramylverbindungen zur behandlung von septischem schock - Google Patents

Muramylverbindungen zur behandlung von septischem schock

Info

Publication number: ATE184883T1
Authority: AT; Austria
Prior art keywords: muramyl; pct; acetyl; date; septic shock
Prior art date: 1991-11-19

Application number

AT92923873T

Other languages

English (en)

Inventor

Roger Aston

Original Assignee

Peptech Uk Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1991-11-19

Filing date

1992-11-19

Publication date

1999-10-15

1991-11-19 Priority claimed from GB919124500A external-priority patent/GB9124500D0/en

1992-05-08 Priority claimed from GB929210013A external-priority patent/GB9210013D0/en

1992-11-19 Application filed by Peptech Uk Ltd filed Critical Peptech Uk Ltd

1999-10-15 Application granted granted Critical

1999-10-15 Publication of ATE184883T1 publication Critical patent/ATE184883T1/de

Links

150000001875 compounds Chemical class 0.000 title abstract 3
206010040070 Septic Shock Diseases 0.000 title abstract 2
230000036303 septic shock Effects 0.000 title abstract 2
239000002158 endotoxin Substances 0.000 abstract 2
206010006895 Cachexia Diseases 0.000 abstract 1
206010063743 Hypophagia Diseases 0.000 abstract 1
PIJXCSUPSNFXNE-QRZOAFCBSA-N N-acetyl-4-(N-acetylglucosaminyl)muramoyl-L-alanyl-D-isoglutamine Chemical compound OC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@@H]1[C@@H](NC(C)=O)[C@H](O)O[C@H](CO)[C@H]1O[C@H]1[C@H](NC(C)=O)[C@@H](O)[C@H](O)[C@@H](CO)O1 PIJXCSUPSNFXNE-QRZOAFCBSA-N 0.000 abstract 1
230000004968 inflammatory condition Effects 0.000 abstract 1
210000002540 macrophage Anatomy 0.000 abstract 1
125000001446 muramyl group Chemical group N[C@@H](C=O)[C@@H](O[C@@H](C(=O)*)C)[C@H](O)[C@H](O)CO 0.000 abstract 1
108090000765 processed proteins & peptides Proteins 0.000 abstract 1
230000001698 pyrogenic effect Effects 0.000 abstract 1
230000006433 tumor necrosis factor production Effects 0.000 abstract 1
208000016261 weight loss Diseases 0.000 abstract 1
230000004580 weight loss Effects 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
- C07K9/001—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence having less than 12 amino acids and not being part of a ring structure
- C07K9/005—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence having less than 12 amino acids and not being part of a ring structure containing within the molecule the substructure with m, n > 0 and m+n > 0, A, B, D, E being heteroatoms; X being a bond or a chain, e.g. muramylpeptides

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Gastroenterology & Hepatology (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Biophysics (AREA)
Biochemistry (AREA)
General Chemical & Material Sciences (AREA)
Immunology (AREA)
Chemical Kinetics & Catalysis (AREA)
Epidemiology (AREA)
Crystallography & Structural Chemistry (AREA)
Rheumatology (AREA)
Pain & Pain Management (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Saccharide Compounds (AREA)

AT92923873T 1991-11-19 1992-11-19 Muramylverbindungen zur behandlung von septischem schock ATE184883T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GB919124500A GB9124500D0 (en)	1991-11-19	1991-11-19	Compounds for medicinal use
GB929210013A GB9210013D0 (en)	1992-05-08	1992-05-08	Compounds for medicinal use

Publications (1)

Publication Number	Publication Date
ATE184883T1 true ATE184883T1 (de)	1999-10-15

Family

ID=26299886

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT92923873T ATE184883T1 (de)	1991-11-19	1992-11-19	Muramylverbindungen zur behandlung von septischem schock

Country Status (9)

Country	Link
US (1)	US5506204A (de)
EP (1)	EP0615522B1 (de)
JP (1)	JP3628689B2 (de)
AT (1)	ATE184883T1 (de)
AU (1)	AU666890B2 (de)
CA (1)	CA2123912C (de)
DE (1)	DE69230041T2 (de)
RU (1)	RU2139086C1 (de)
WO (1)	WO1993010148A1 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9320820D0 (en) *	1993-10-08	1993-12-01	Biokine Tech Ltd	Compounds for medicinal use
GB9413935D0 (en) *	1994-07-11	1994-08-31	Peptech Uk Ltd	Use of maramyl peptide compounds
GB9419011D0 (en) *	1994-09-21	1994-11-09	Peptech Uk Ltd	Use of muramyl peptide compounds
WO1997005889A1 (en) *	1995-08-03	1997-02-20	Slesarev Vladimir I	Non-specific vaccination by d-amino-acid containing compounds
US6200955B1 (en) *	1996-06-11	2001-03-13	Commonwealth Biotechnologies, Inc.	Heparin binding peptides
US5834435A (en) *	1996-11-27	1998-11-10	Slesarev; Vladimir I.	Inhibition of TNF-α pleiotropic and cytotoxic effects
EP1053001B1 (de)	1998-02-13	2010-12-15	Amylin Pharmaceuticals, Inc.	Neue verbindungen mit gemischter amylin aktivität
BR0109968A (pt)	2000-04-18	2003-05-27	Lilly Co Eli	Processo para a preparação de lipìdeo ii
WO2001079268A2 (en) *	2000-04-18	2001-10-25	Eli Lilly And Company	A glycopeptide and preparation thereof
US7112564B2 (en) *	2003-04-09	2006-09-26	Zylacta Corporation	Biodegradable glucosaminemuramyl peptides for apoptosis modulation
WO2005007676A2 (en) *	2003-07-10	2005-01-27	Rajadhyaksha V J	Glycopeptides for the treatment of als and other metabolic and autoimmune disorders
RU2412197C2 (ru) *	2006-07-06	2011-02-20	Попилюк Сергей Федорович	Полимерный фрагмент пептидогликана клеточной стенки грамотрицательных бактерий, способ его получения и его применение в качестве иммуностимулятора
ES2856081T3 (es)	2007-04-16	2021-09-27	Occlutech Holding Ag	Oclusor para la oclusión de una orejuela auricular y procedimiento de producción del mismo
WO2008131074A1 (en)	2007-04-19	2008-10-30	University Of Pittsburgh - Of The Commonwealth System Of Higher Education	Use of toll-like receptor-9 agonists, toll-like receptor-4 antagonists, and/or nuclear oligomerization domain-2 agonists for the treatment or prevention of toll-like receptor-4-associated disorders
US8518903B2 (en)	2007-04-19	2013-08-27	University of Pittsburgh—of the Commonwealth System of Higher Education	Use of toll-like receptor-9 agonists
RU2336897C1 (ru) *	2007-04-28	2008-10-27	Федеральное государственное учреждение здравоохранения "Ростовский-на-Дону научно-исследовательский противочумный институт" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека	Способ терапии токсического шока у лабораторных животных при экспериментальной чуме
US9072760B2 (en)	2010-09-24	2015-07-07	University of Pittsburgh—of the Commonwealth System of Higher Education	TLR4 inhibitors for the treatment of human infectious and inflammatory disorders
US10668092B2 (en)	2010-09-24	2020-06-02	The John Hopkins University	Compositions and methods for treatment of inflammatory disorders
WO2012088425A2 (en)	2010-12-22	2012-06-28	University Of Pittsburgh - Of The Commonwealth System Of Higher Education	Gap junction-enhancing agents for treatment of necrotizing enterocolitis and inflammatory bowel disease
WO2014052453A1 (en)	2012-09-25	2014-04-03	University Of Pittsburgh - Of The Commonwealth System Of Higher Education	Oral therapy of necrotizing enterocolitis
EA025690B1 (ru) *	2014-07-15	2017-01-30	Государственное бюджетное образовательное учреждение высшего профессионального образования "Курский государственный медицинский университет" Министерства здравоохранения Российской Федерации	Ранозаживляющее средство, обладающее иммуностимулирующим и антиоксидантным эффектами
RU2584089C1 (ru) *	2015-06-15	2016-05-20	Государственное Бюджетное Образовательное Учреждение Высшего Профессионального Образования "Саратовский Государственный Медицинский Университет Имени В.И. Разумовского" Министерства Здравоохранения Российской Федерации	Способ снижения летального эффекта бактериального липополисахарида in vitro
CA3021645A1 (en)	2016-04-29	2017-11-02	Icahn School Of Medicine At Mount Sinai	Targeting the innate immune system to induce long-term tolerance and to resolve macrophage accumulation in atherosclerosis
AU2022239614A1 (en)	2021-03-19	2023-10-12	Icahn School Of Medicine At Mount Sinai	Compounds for regulating trained immunity, and their methods of use

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SU727647A1 (ru) *	1977-11-02	1980-04-15	Институт биоорганической химии им.М.М.Шемякина	Гликопептиды,обладающие противоопухолевой активностью и способ их получени
JPS5543030A (en) *	1978-09-21	1980-03-26	Dai Ichi Seiyaku Co Ltd	Prophylactic and remedy for microbial infection disease
FR2449697A1 (fr) *	1979-02-20	1980-09-19	Anvar	Nouveaux muramyl-peptides substitues sur un azote peptidique et medicaments les contenant
JP2545279B2 (ja) *	1987-09-02	1996-10-16	第一製薬株式会社	血小板減少予防及び治療剤
SU1671310A1 (ru) *	1989-01-30	1991-08-23	Всесоюзный Научно-Исследовательский Институт Экспериментальной Ветеринарии Им.Я.Р.Коваленко	Способ профилактики вирусных заболеваний птиц

1992
- 1992-11-19 RU RU94027574A patent/RU2139086C1/ru active
- 1992-11-19 AU AU29492/92A patent/AU666890B2/en not_active Expired
- 1992-11-19 DE DE69230041T patent/DE69230041T2/de not_active Expired - Lifetime
- 1992-11-19 AT AT92923873T patent/ATE184883T1/de active
- 1992-11-19 JP JP50910693A patent/JP3628689B2/ja not_active Expired - Lifetime
- 1992-11-19 WO PCT/GB1992/002137 patent/WO1993010148A1/en not_active Ceased
- 1992-11-19 EP EP92923873A patent/EP0615522B1/de not_active Expired - Lifetime
- 1992-11-19 CA CA002123912A patent/CA2123912C/en not_active Expired - Lifetime
- 1992-11-19 US US08/244,154 patent/US5506204A/en not_active Expired - Lifetime

Also Published As

Publication number	Publication date
AU2949292A (en)	1993-06-15
CA2123912A1 (en)	1993-05-27
EP0615522B1 (de)	1999-09-22
EP0615522A1 (de)	1994-09-21
DE69230041D1 (de)	1999-10-28
RU2139086C1 (ru)	1999-10-10
DE69230041T2 (de)	2000-01-05
AU666890B2 (en)	1996-02-29
JPH07508497A (ja)	1995-09-21
CA2123912C (en)	2007-04-17
WO1993010148A1 (en)	1993-05-27
JP3628689B2 (ja)	2005-03-16
US5506204A (en)	1996-04-09
RU94027574A (ru)	1996-07-20

Publication	Publication Date	Title
DE69230041D1 (de)	1999-10-28	Muramylverbindungen zur behandlung von septischem schock
ATE225176T1 (de)	2002-10-15	Verwendung von serotonin-antagonisten (5ht3) zur behandlung von fibromyalgie
DE69421912D1 (de)	2000-01-05	Methode zur behandlung von wasser
ZA963593B (en)	1996-11-25	IL-6 activity inhibitor
GB9323165D0 (en)	1994-01-05	Compounds
PT988301E (pt)	2006-10-31	Acetais ciclicos de imidazolilo
DE69331665D1 (de)	2002-04-11	Methode zur behandlung von nukleinsäureproben
DE69527765D1 (de)	2002-09-19	Verwendung von Hyaluronsäure oder sein Salz zur Behandlung von Hauterkrankungen
DE69634900D1 (de)	2005-08-04	Proteintyrosine-kinaseinhibitoren zur behandlung der osteoarthritis
DE69427869D1 (de)	2001-09-06	Botulinumtoxine zur behandlung von hyperhydrosis
DE59201870D1 (de)	1995-05-18	Verfahren zur Herstellung von substituierten Malonesteraniliden und Malonsäure-monoaniliden.
MY101842A (en)	1992-01-31	Treatment of oral diseases.
DE69004081D1 (de)	1993-11-25	Verwendung der Stearidonsäure zur Behandlung von Entzündungserkrankungen.
GB9924957D0 (en)	1999-12-22	Novel treatment
GB9506684D0 (en)	1995-05-24	Control of pod dehiscence
ATE196083T1 (de)	2000-09-15	Verwendung von ferrioxamin-b zur behandlung septischen schocks
DE69433978D1 (de)	2004-10-07	Methode der spezifischen abschaltung von genen durch dna-methylierung
DE69129953D1 (de)	1998-09-17	Verwendung von Bisphosphonsäure zur Behandlung von Störungen des Kalziummetabolismus
DE59202663D1 (de)	1995-08-03	Verwendung eines UV-Strahlers zur Behandlung von Oberflächen.
ATE198751T1 (de)	2001-02-15	Azoderivate von 5-aminosalicylsäure zur behandlung von enzündlichen darmerkrankungen
DE69328615D1 (de)	2000-06-15	Verfahren zur behandlung von viehhaltungsgülle
DE69300667D1 (de)	1995-11-23	Verfahren zur thermischen Behandlung von verbrauchten Auskleidungen aus elektrolytischen Hall-Heroult Zellen.
ATE410181T1 (de)	2008-10-15	Verwendung von intereferon gamma zur behandlung von herzhypertrophie
ATE270102T1 (de)	2004-07-15	Verwendung von benzopyranolen zur behandlung von neurologischen erkrankungen
ATE209891T1 (de)	2001-12-15	Verwendung von 1-hydroxy-2-pyridonen zur behandlung der seborrhoischen dermatitis